Search

Your search keyword '"Routy, Bertrand"' showing total 524 results

Search Constraints

Start Over You searched for: Author "Routy, Bertrand" Remove constraint Author: "Routy, Bertrand"
524 results on '"Routy, Bertrand"'

Search Results

101. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in advanced non-small cell lung cancer patients

102. Characterization of Alistipes montrealensis sp. nov., Isolated from Human Feces of a Patient with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors

103. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

104. A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota

105. Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032)

106. Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis

107. Tractidigestivibacter montrealensis sp. nov., a new member of human gut microbiota isolated from a healthy volunteer.

108. 50: Prospective Neurocognitive Functions of Patients Treated with Concurrent Nivolumab and Stereotactic Brain Radiosurgery for NSCLC and RCC Brain Metastases

109. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study

110. CANCER IMMUNOTHERAPY: Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

112. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies

113. Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy

114. Cancer induces a stress ileopathy depending on B-adrenergic receptors and promoting dysbiosis that contribute to carcinogenesis

115. Immunodynamics of explanted human tumors for immuno‐oncology

116. Gut microbiota influence anastomotic healing in colorectal cancer surgery through modulation of mucosal proinflammatory cytokines

118. Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.

120. A phase II trial combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC.

121. Thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.

122. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

123. Circulating β-d-Glucan as a Marker of Subclinical Coronary Plaque in Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus

126. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

128. A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

130. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

133. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

134. Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients

135. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

136. 724 MUCOSA-ADHERENT BACTERIA REGULATE THE HEALING OF COLONIC ANASTOMOTIC WOUNDS IN COLORECTAL CANCER SURGERY

138. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.

139. 681 Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors

140. 679 High fiber diet modifies gut microbiome, propionate production, intratumor immune response and is associated with outcome in patients with lung cancer treated with immune checkpoint inhibitors

141. High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

142. Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors

143. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

144. Abstract S12-01: High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia

145. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion

146. Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota

148. Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

149. Abstract 5730: A new polyphenol prebiotic isolated from Myrciaria dubia improves gut microbiota composition and increases anti-PD-1 efficacy in murine cancer models

150. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

Catalog

Books, media, physical & digital resources